Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Shareholder vote
confidence 98%
filed 2026-06-26
Item 5.07
AES shareholders voted on June 26, 2026 at a special meeting to approve the proposed acquisition by a consortium led by Global Infrastructure Partners and EQT, with the merger proposal passing with 97.92% of votes cast in favor (479,072,642 votes). The transaction is valued at approximately $10.7 billion in equity value and $33.4 billion enterprise value, and the HSR Act waiting period expired on June 22, 2026, clearing a major regulatory condition for the acquisition.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 98%
filed 2026-06-26
Item 1.01
VeriSign completed a registered offering of $550 million aggregate principal amount of 5.100% Senior Notes due 2031 on June 26, 2026. This is a material creation of a new direct financial obligation under a supplemental indenture, clearly fitting the debt_issuance category. The substantial principal amount and senior unsecured status make this material to investors assessing the company's capital structure and financial obligations.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-06-26
Item 1.01
Allegiant issued $650 million in aggregate principal amount of 7.125% Senior Secured Notes due 2031 on June 24, 2026. The company used proceeds to repurchase $377.5 million of existing 7.25% notes due 2027 and for general corporate purposes, representing a material refinancing activity.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 98%
filed 2026-06-26
EX-99.1
The exhibit is a press release announcing the results of Highlander Silver's annual general meeting of shareholders held on June 25, 2026. It discloses the approval of all matters presented, including the election of six directors and re-appointment of auditors, with detailed voting results for each director nominee. This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, and is material as it confirms the composition of the board of directors.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-06-26
EX-99.1
This press release discloses the voting results from Fury Gold Mines' Annual General Meeting held on June 25, 2026, including shareholder approval of: (1) fixing the board at six directors; (2) election of all six director nominees; (3) appointment of PricewaterhouseCoopers LLP as auditor; and (4) renewal of the long-term incentive plan for three years. The disclosure directly matches the `shareholder_vote_results` taxonomy entry, which covers results of votes at annual or special meetings of security holders. Board elections and auditor appointments are material governance matters affecting investor assessment of the company's leadership and financial oversight.
View raw filing on EDGAR →
6-K
Earnings release
confidence 75%
filed 2026-06-26
EX-99.1
This is a notice announcing the forthcoming release of second quarter 2026 operating and financial results on July 28, 2026, with a conference call scheduled for July 29, 2026. While the actual results are not disclosed in this exhibit, the document is a press release announcing the timing and logistics of the earnings release event, which is a material disclosure to investors regarding when quarterly financial results will be publicly available.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 98%
filed 2026-06-26
EX-99.1
This press release announces the results of Titan Mining's annual shareholders' meeting held on June 25, 2026. It discloses the approval of three matters: setting the board size at seven directors, election of all seven director nominees (with detailed voting results for each), and re-appointment of Ernst & Young LLP as auditors. The detailed vote tallies for each director nominee are the core disclosure, matching the shareholder_vote_results category precisely.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-26
Item 5.07
EDAP TMS SA held its 2026 Annual General Meeting on June 26, 2026, with comprehensive shareholder voting results disclosed across 32 resolutions covering director elections, financial statement approvals, executive compensation advisory votes, capital delegation authorities, and bylaw amendments.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-26
Item 5.07
SCYNEXIS held its Annual Meeting of Stockholders on June 25, 2026, at which shareholders voted on and approved six proposals: election of directors, ratification of auditors, advisory votes on executive compensation, amendment to the equity incentive plan, and amendment to the Certificate of Incorporation to increase authorized shares.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-26
Item 8.01
An S-3 registration statement became effective for the resale of up to 87 million shares by selling stockholders, including 8.75 million shares from pre-funded warrants and 43.5 million shares from common warrants with a $1.20 exercise price, representing a substantial dilutive issuance to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-26
Item 1.01
REalloys completed a private placement of 7,017,540 shares of common stock at $14.25 per share, raising approximately $100 million in gross proceeds. The unregistered shares were issued under Section 4(a)(2) and Rule 506(b) exemptions to institutional and accredited investors, with the company agreeing to file a resale registration statement.
View raw filing on EDGAR →
8-K
Covenant Breach
confidence 95%
filed 2026-06-26
Item 2.04
The Company received a notice of Event of Default from ADI Funding, LLC on June 11, 2026, asserting breach of the 8% secured promissory note ($271,739.13 principal) based on failure to file a resale registration statement, Form 8-K, and transfer agent instructions by the specified deadline. The Holder may exercise acceleration of debt, enforcement of collateral, and recovery of attorneys' fees if the default is not cured within ten trading days, triggering Item 2.04's requirement to disclose events that accelerate or increase direct financial obligations.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 92%
filed 2026-06-26
EX-99.1
This exhibit is a written board resolution approving one-time performance bonuses for two named executives: Ms. Zhang Fan (Business Development Director) receives US$200,000 and Mr. Fu Xiaowei (CEO and Executive Director) receives US$300,000 for services rendered during 2025. The bonuses may be paid in cash or equivalent Class A ordinary shares. This is a direct disclosure of compensatory arrangements for named executives, fitting the exec_compensation category.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 85%
filed 2026-06-26
KB Securities, a wholly-owned subsidiary of KB Financial Group, resolved on June 26, 2026 to increase its capital through issuance of 56,753,688 common shares at KRW 17,620 per share, generating approximately KRW 1 trillion in proceeds. This is a material capital raise by a significant subsidiary that will dilute existing shareholders' ownership and is disclosed as a discrete corporate action rather than a periodic financial report.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-26
Item 5.07
This is a clear disclosure of shareholder voting results from the 2026 Annual Meeting of Stockholders held on June 23, 2026. The filing reports final voting tallies for two proposals: election of two Class III directors (Jae Chang and David H. Park) and ratification of CBIZ CPAs P.C. as independent auditor. Both proposals passed with overwhelming support, and the disclosure includes detailed vote counts and quorum information, which is the standard content for Item 5.07 shareholder vote results.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 85%
filed 2026-06-26
Item 1.01
The filing discloses Amendment No. 1 to the Senior Credit Facilities, which refinanced $600 million in term loans at reduced interest rate margins and repriced the revolving credit commitments. While technically an amendment to an existing credit agreement rather than a new debt issuance, the refinancing of $600 million in principal with new terms and the participation of new lenders constitutes a material modification of the registrant's direct financial obligations. This is material to investors as it affects the company's debt structure, interest expense, and financial flexibility.
View raw filing on EDGAR →
6-K
M&A activity
confidence 92%
filed 2026-06-26
SK Telecom's board approved a capital contribution commitment to acquire 1,198 newly issued shares of SK hynix NAND Product Solutions Corp. for 738.384 billion Won (approximately 5.70% of SK Telecom's total shareholders' equity), representing a material equity investment in an affiliated company. The transaction is structured as a commitment agreement with a scheduled completion date of June 25, 2030, and is explicitly undertaken to facilitate synergies with the Company's AI business, meeting the definition of material acquisition activity under Item 1.01.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-06-26
The filing announces multiple executive leadership appointments effective 1 July and 1 September 2026, including Jessica Farrell as President North America, Edgar Basto transitioning to Chief Enterprise Performance Officer, and Geraldine Slattery assuming expanded responsibilities as President Australia. While Brandon Craig's CEO appointment was previously announced on 18 March 2026, this disclosure announces the broader executive team restructuring and new appointments that would materially affect investor assessment of leadership capacity and organizational structure.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-06-26
This 6-K furnishes the notice of resolutions from the 24th Ordinary General Meeting of Shareholders held on June 26, 2026. It discloses the results of shareholder votes on four proposals: approval of dividend appropriation (¥79 per share), approval of articles amendments including a 2-for-1 stock split effective October 1, 2026, election of thirteen directors (including one new director, Takeshi Mikami), and disapproval of a shareholder proposal on share repurchase authority. These are material shareholder vote results under Item 5.07 equivalent, affecting capital structure, governance, and dividend policy.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-26
Item 5.02
The Board unanimously elected Anne DelSanto as an independent director effective July 1, 2026, increasing the Board size from six to seven members. Ms. DelSanto, with 30+ years of technology industry experience in cloud computing, SaaS, and AI, was also appointed to the Compensation Committee, strengthening the Board's expertise in areas aligned with the Company's strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-26
Item 5.02
Jade Biosciences appointed Mark Eisner, M.D., M.P.H., to its Board of Directors as a Class I director and member of the Nominating and Corporate Governance Committee, effective June 25, 2026. Dr. Eisner brings 25+ years of clinical development and immunology leadership, including prior roles as Chief Medical Officer at Vir Biotechnology and FibroGen, and 11 years at Genentech/Roche, directly supporting the company's pipeline advancement.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-06-26
Item 2.02
Cineverse issued a press release on June 26, 2026 announcing financial results for the three and twelve months ended March 31, 2026 (Q4 FY 2026 and full-year FY 2026). The disclosure includes quarterly and annual revenue ($26.0M and $65.7M respectively), net income, Adjusted EBITDA, and forward guidance for fiscal 2027 ($115–$120M revenue, $10–$20M Adjusted EBITDA). This is a standard earnings release attached as Exhibit 99.1 and disclosed under Item 2.02, which is material to investors assessing the company's financial performance and growth trajectory.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-26
Item 8.01
The Company has agreed to issue 3,453,237 common shares valued at $4,800,000 to settle and terminate an offtake agreement with Vox Royalty entities. This is a material issuance of equity securities as consideration for a contract termination, which will be registered on Form S-3. The substantial share count and dollar value represent a dilutive capital event that would materially affect investor assessment of ownership and capitalization.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-26
Item 5.07
This Item 5.07 discloses the results of a special shareholder meeting held on June 22, 2026, where shareholders voted on the Scheme of Arrangement to approve Wave Life Sciences' redomiciliation from Singapore to another jurisdiction. The filing reports final voting results (155,190,836 shares voted in favor, 78,429 against, with 87 shareholders voting in favor and 0 against), which is the core disclosure required under Item 5.07. The redomiciliation is a material corporate restructuring requiring court and shareholder approval.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-06-26
Item 5.02
Donald S. Poulton's retirement effective June 30, 2026, from his position as Chief Executive Officer of Medallion Bank is the principal disclosed action. While the section also addresses compensatory arrangements (accelerated vesting of 92,978 restricted shares and discretionary bonus eligibility), the core event is the departure of the CEO. The compensation details are ancillary consequences of the retirement rather than the primary focus of the disclosure.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-06-26
Item 3.03
Quince Therapeutics effectuated a 1-for-20 reverse stock split on June 26, 2026, pursuant to stockholder approval obtained on June 11, 2026, via a Certificate of Amendment filed with Delaware. The reverse split modifies the capital structure and trading characteristics of the company's common stock by combining shares, though it does not alter ownership percentages or the fundamental rights and preferences of the securities.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-06-26
The 6-K discloses the results of Pharvaris N.V.'s Annual General Meeting of Shareholders held on June 26, 2026, including shareholder votes on adoption of annual accounts, appointment of external auditor (PricewaterhouseCoopers Accountants N.V.), director discharge, share acquisition authorization extension, and re-appointment of Dr. Margareta Elisabeth Björk as non-executive director. This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, and the outcomes (particularly auditor appointment and director re-appointment) are material to investors' assessment of governance and financial oversight.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 85%
filed 2026-06-26
Item 8.01
Mills Music Trust issued a Quarterly Distribution Report disclosing a distribution of $93,323 ($0.3360 per Trust Unit) to Unit Holders from Q1 2026 royalty payments received from Sony Music Publishing. This is a routine but material distribution of cash to security holders from trust income, consistent with the trust's ordinary business of collecting and distributing royalty payments on its copyright catalogue.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 98%
filed 2026-06-26
EX-99.1
This exhibit is an official announcement of poll results from XPeng Inc.'s Annual General Meeting held on June 26, 2026. It discloses the voting outcomes on ten resolutions, including adoption of audited financial statements, re-election of independent non-executive directors (Donghao Yang, HongJiang Zhang, Yudong Chen), authorization of director remuneration, re-appointment of auditors (PricewaterhouseCoopers), and approval of general mandates for share issuance, repurchase, and amendments to the memorandum and articles of association. All resolutions passed with disclosed vote counts and percentages, meeting the definition of shareholder_vote_results under Item 5.07 equivalent disclosure.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 95%
filed 2026-06-26
The 6-K furnishes a Pricing Agreement dated June 18, 2026 for three series of Fixed-to-Floating Rate Senior Callable Notes (due 2030, 2032, and 2037) with coupon rates of 4.911%, 5.102%, and 5.586% respectively, along with supplemental indentures and global security forms. This constitutes creation of new direct financial obligations through debt issuance, a material capital event for a large financial institution.
View raw filing on EDGAR →
8-K
Earnings release
confidence 92%
filed 2026-06-26
Item 2.02
Fidelity Private Credit Fund disclosed its financial results and performance as of May 31, 2026, including monthly and period-to-date net returns across share classes, NAV per share of $24.88, distribution rate of 9.21%, total assets of $2.6 billion, and portfolio metrics.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-26
Item 3.02
Silver Point Private Credit Fund issued and sold 745,920 unregistered common shares for approximately $20 million pursuant to subscription agreements, relying on Section 4(a)(2) and Regulation D exemptions.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-06-26
Item 8.01
The Board of Trustees declared a regular monthly dividend of $0.1575 per share payable to common shareholders as of June 30, 2026.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-06-26
Item 2.02
Worthington Enterprises disclosed unaudited financial results for the fourth quarter and full fiscal year 2026 ended May 31, 2026, via conference call transcript, reporting net sales of $1.4 billion (20% growth), adjusted EBITDA of $296 million (12% growth), and earnings per share of $3.14 GAAP and $3.37 adjusted, with segment performance and management commentary on business operations and outlook.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-26
Item 5.02
The Compensation Committee approved on June 22, 2026, a special leadership retention performance share award of 25,000 Performance Shares each for four named executives (Colin J. Souza, Patrick J. Kennedy, Steven M. Caravati, and James R. Bowes), subject to performance-based vesting conditions tied to adjusted EBITDA and return on assets targets for fiscal 2027–2030 and a retention condition.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-26
Item 5.02
Kristen L. Soler, Executive Vice President and Chief Human Resources Officer, is departing the Company effective June 26, 2026, to pursue other opportunities. The disclosure explicitly states she will serve in an advisory capacity through July 10, 2026, and will receive severance payment under the termination without due cause provision of her employment agreement. This is a clear executive departure of a named officer.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-26
Item 5.02
Robert Lally, Senior Vice President of Finance and Operations and principal accounting officer, resigned effective July 22, 2026. The departure of a principal accounting officer is material to investors as it affects financial reporting oversight and internal controls. The filing explicitly states the resignation was not due to disagreement, but the loss of this key finance and accounting leadership role remains a material event.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-06-26
Item 1.01
ALX Oncology entered into a loan and security agreement with HSBC Ventures USA Inc. on June 25, 2026, establishing a secured multi-tranche term loan facility of up to $50 million with $10 million borrowed at closing, maturing June 1, 2030. The company simultaneously terminated its prior loan agreement dated October 27, 2022, by using proceeds from the new facility to pay off all outstanding amounts, constituting a material debt refinancing transaction.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-26
Item 5.07
Stockholders voted at the Annual Meeting on five proposals: election of two Class III directors (Bridget Martell and Carole Nuechterlein), ratification of Ernst & Young LLP as auditor, approval of an amendment to the 2020 Employee Stock Purchase Plan (ESPP) reserving an additional 500,000 shares and eliminating the evergreen provision, advisory vote on named executive officer compensation, and advisory vote on the frequency of future compensation votes. The filing discloses the tabulated voting results for each proposal.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-26
Item 5.07
This is a clear disclosure of shareholder vote results from Cambium Networks' annual general meeting held on June 25, 2026. The filing reports voting outcomes on seven proposals including director elections, auditor ratification, say-on-pay, reverse share split approval, and bylaw amendments. Item 5.07 is the designated 8-K item for shareholder vote results, and the detailed vote tallies for each proposal directly match that requirement. The reverse share split approval and related amendments are material corporate actions requiring shareholder approval.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-26
Item 3.02
The filing discloses an unregistered sale of 8,677,493 common shares for $250 million on June 23, 2026, pursuant to capital drawdown notices to investors. This is a classic dilutive equity issuance exempt under Section 4(a)(2) and Regulation D, representing a material capital raise that would affect investor assessment of ownership dilution and the company's capital structure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-26
Item 5.07
MYOMO held its Annual Meeting of Stockholders on June 25, 2026, with shareholders voting on seven matters including director elections, executive compensation advisory vote, auditor ratification, stock plan amendment, charter amendment, director classification proposal, and meeting adjournment authority.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-06-26
Item 5.02
Stockholders approved an amendment to the Myomo 2018 Stock Option and Incentive Plan increasing available shares by 1,833,000, expanding the pool of equity grants available to officers and directors.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 95%
filed 2026-06-26
EX-99.1
This announcement discloses a grant of 1,890,627 restricted share units (RSUs) to certain employees of Bilibili Inc. pursuant to the Second Amended and Restated 2018 Share Incentive Plan on June 26, 2026. The grant represents approximately 0.45% of total shares outstanding and includes vesting schedules (June 2027–2030) and clawback provisions. This is a compensatory arrangement for employees and falls squarely within exec_compensation disclosure requirements, as it involves equity grants to incentivize and retain key personnel.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-26
Item 3.02
The filing discloses an unregistered sale of 1,527,300.4964 common shares for $40 million on June 24, 2026, pursuant to capital drawdown notices. This is a classic dilutive issuance under Item 3.02, exempt from registration under Section 4(a)(2) and Regulation D. The $40 million capital raise is material to a trust-based investment vehicle and would affect investor assessment of ownership dilution and capital structure.
View raw filing on EDGAR →
6-K
M&A activity
confidence 92%
filed 2026-06-26
The 6-K discloses court approval and shareholder approval of a statutory scheme of arrangement and redomiciliation whereby Marex Group plc (UK) will be replaced by New Marex (Bermuda) as the parent holding company, with each ordinary share cancelled and exchanged for one new ordinary share. This constitutes a material change of control and corporate restructuring. The effective date is July 1, 2026, with trading transition on Nasdaq under the same ticker symbol.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-26
Item 3.02
The filing discloses an unregistered sale of 1,146,788.9908 common shares for $30,000,000 on June 24, 2026, pursuant to capital drawdown notices under Section 4(a)(2) and Regulation D/S exemptions. This is a classic dilutive equity issuance that would materially affect investor assessment of ownership dilution and capital structure.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 92%
filed 2026-06-26
EX-99.1
This exhibit is a post-buyback public announcement for Wipro's repurchase of 60 crore (600 million) fully paid equity shares at ₹250 per share. Share buyback programs are a form of capital return to shareholders and fall within the dividend_distribution category, which explicitly includes "share-repurchase programs." The material scale (600 million shares) and formal regulatory submission to BSE, NSE, and NYSE make this a material disclosure affecting investor assessment of capital allocation.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-26
Item 5.07
This Item 5.07 disclosure reports the results of BCP Investment Corporation's annual meeting of stockholders held on June 25, 2026, including voting outcomes for two proposals: election of three directors (Jennifer Kwon Chou, Joseph Morea, and Robert Warshauer) and ratification of Deloitte & Touche LLP as independent auditor. The tabulated vote counts for each proposal are provided, which is the core content of a shareholder vote results disclosure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-06-26
Item 5.02
The filing discloses two executive changes: the departure of Chief Accounting Officer Yanina Grant-Huerta (effective July 17, 2026) and the appointment of Kevin G. Sarney as interim CFO and principal accounting officer (effective June 26, 2026). While both events are disclosed, the principal action centers on the appointment of Sarney to fill the critical CFO and principal accounting officer roles, making exec_appointment the most salient classification. The departure is secondary context to the appointment action.
View raw filing on EDGAR →